NF-κB induces abnormal centrosome amplification by upregulation of CDK2 in laryngeal squamous cell cancer
- PMID: 21769424
- DOI: 10.3892/ijo.2011.1125
NF-κB induces abnormal centrosome amplification by upregulation of CDK2 in laryngeal squamous cell cancer
Abstract
Centrosome amplification can drive chromosomal instability (CIN) which is a major source of tumor initiation. The present study aimed to investigate the impact of nuclear factor kappa B (NF-κB) on centrosome amplification of Hep-2 cells. Immunofluorescence was performed to display centrosomes. BAY11-7082 was used as an inhibitor of NF-κB to assess the inhibition of centrosome amplification, and cyclin-dependent kinase 2 (CDK2), ensuring cell cycle cycle coordination with centrosome cycle was detected by Western blotting. Furthermore, a 1556-bp fragment of the CDK2 promoter was analyzed using the TRANSFAC-TESS software. Luciferase assay, including a series of truncated CDK2 promoters and site mutations, was carried out to determine NF-κB binding sites in the CDK2 promoter. Electrophoresis mobility shift and chromatin immunoprecipitation assays were applied to confirm whether NF-κB indeed binds to the 5'-promoter region of the CDK2 gene. To reveal the clinical significance of CDK2 expression in laryngeal squamous cell cancer, mRNA and protein levels were assessed by RT-PCR and Western blotting, respectively. We found that the transcription factor NF-κB plays a role in centrosome amplification in Hep-2 cells. Centrosome amplification is reduced by inhibition of the NF-κB pathway. Moreover, expression of the p65 subunit of NF-κB is sufficient to promote centrosome amplification and increase in CDK2 protein levels. We further identified a functional NF-κB binding site located in the CDK2 promoter. Single mutation of the NF-κB site III (construct mutIII) however resulted in 76±5% (p<0.01) luciferase activity reduction. Electromobility shift assays and chromatin immunoprecipitaton results suggest that NF-κB indeed binds to this responsive element associating with CDK2 expression and centrosome amplification. RT-PCR and Western blotting results revealed that both mRNA and protein levels of CDK2 were significantly higher in tumor tissues than those in paired adjacent normal laryngeal tissues.
Similar articles
-
Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment.Apoptosis. 2008 Jun;13(6):756-70. doi: 10.1007/s10495-008-0210-0. Apoptosis. 2008. PMID: 18421578
-
In vivo binding of NF-kappaB to the IkappaBbeta promoter is insufficient for transcriptional activation.Biochem J. 2006 Nov 15;400(1):115-25. doi: 10.1042/BJ20060786. Biochem J. 2006. PMID: 16792530 Free PMC article.
-
Characterization of the human intestinal CD98 promoter and its regulation by interferon-gamma.Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G535-45. doi: 10.1152/ajpgi.00385.2006. Epub 2006 Oct 5. Am J Physiol Gastrointest Liver Physiol. 2007. PMID: 17023546
-
Targeting CDK2 in cancer: challenges and opportunities for therapy.Drug Discov Today. 2020 Feb;25(2):406-413. doi: 10.1016/j.drudis.2019.12.001. Epub 2019 Dec 10. Drug Discov Today. 2020. PMID: 31839441 Review.
-
Pathways sufficient to induce epidermal carcinogenesis.Cell Cycle. 2004 May;3(5):621-4. Epub 2004 May 15. Cell Cycle. 2004. PMID: 15044848 Review.
Cited by
-
HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib.Front Pharmacol. 2022 Jun 3;13:864194. doi: 10.3389/fphar.2022.864194. eCollection 2022. Front Pharmacol. 2022. PMID: 35721157 Free PMC article.
-
Integrative Bioinformatics Approaches to Map Potential Novel Genes and Pathways Involved in Ovarian Cancer.Front Bioeng Biotechnol. 2019 Dec 17;7:391. doi: 10.3389/fbioe.2019.00391. eCollection 2019. Front Bioeng Biotechnol. 2019. PMID: 31921802 Free PMC article.
-
lncRNA-NKILA/NF-κB feedback loop modulates laryngeal cancer cell proliferation, invasion, and radioresistance.Cancer Med. 2018 May;7(5):2048-2063. doi: 10.1002/cam4.1405. Epub 2018 Mar 23. Cancer Med. 2018. PMID: 29573243 Free PMC article.
-
Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression?Front Pharmacol. 2013 Feb 12;4:13. doi: 10.3389/fphar.2013.00013. eCollection 2013. Front Pharmacol. 2013. PMID: 23408731 Free PMC article.
-
Emerging Roles for Transcription Factors During Mitosis.Cells. 2025 Feb 12;14(4):263. doi: 10.3390/cells14040263. Cells. 2025. PMID: 39996736 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources